Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Conditions

• Lung Adenocarcinoma Stage III
• Lung Adenocarcinoma Stage IV
• EGFR Gene Mutation

Interventions

• DRUG: Furmonertinib
• DRUG: Bevacizumab

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China